Participants in the study will receive either aprepitant or a placebo, which is a substance with no active medication. The study will observe the effects of aprepitant on patients undergoing different types of bariatric surgery, such as laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, or one-anastomosis mini gastric bypass. The trial will monitor the incidence and severity of PONV, as well as the need for additional medication to manage symptoms.

The study will also look at other factors, such as the length of stay in the recovery room and overall hospital stay, as well as patient satisfaction with their postoperative experience. By understanding how aprepitant affects these outcomes, the trial hopes to improve the recovery process for patients undergoing bariatric surgery.